ReviewNature reviews. Disease primers2023
HIV-associated lung disease.
Review in Nature reviews. Disease primers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Effect of HIV on respiratory symptoms, health status, and exertional capacity.AIDS (London, England) · 2025Pooled it
- Effect of Human Immunodeficiency Virus on Lung Function and Structure: A Systematic Review and Meta-Analysis.Annals of the American Thoracic Society · 2025Pooled it
- Development and internal validation of a CT radiomics-based model for severity classification in HIV-associatedJournal of thoracic disease · 2026Article
- HIV-driven virome dysbiosis unveils distinct virome features and inter-viral correlations in blood and respiratory niches.Communications biology · 2026Article
- Initial stage analysis of tislelizumab in combination with chemotherapy for patients with advanced HIV-positive non-small-cell lung cancer: a comparative clinical trial.Anti-cancer drugs · 2026Article
- Associations between serological evidence of SARS-CoV-2 infection and longitudinal pulmonary outcomes among people with HIV: analysis of the MACS/WIHS combined cohort study (MWCCS).Respiratory research · 2026Article
- Continuous antiretroviral therapy induces progressive senescence-like reprogramming of alveolar macrophages.Frontiers in immunology · 2026Article
- Immune imbalance markers: key factors in early recognition of multidrug-resistant bacterial infections in non-immunocompromised VAP patients.Frontiers in immunology · 2026Article
- Greater ambient air pollution exposure is associated with worse respiratory symptoms in men and women with HIV and chronic lung disease: a cohort study.Respiratory research · 2025Article
- Plasma IL-6 level predict the risk of in-hospital mortality in HIV-associated pneumocystis pneumonia.BMC infectious diseases · 2025Article
- Global burden of HIV and drug-resistant tuberculosis co-infection and its attributable risk factors, 1990 to 2021, with projections to 2031.BMC infectious diseases · 2025Article
- Opportunistic use of artificial intelligence with X-ray imaging for diagnosis of HIV status in tuberculosis patients in Uganda and Tanzania.PLOS digital health · 2025Article
- Association between exposure to polycyclic aromatic hydrocarbons and infections with human papillomavirus and herpes simplex virus type 2.Scientific reports · 2025Article
- Incidence of Confirmed Influenza and Pneumococcal Infections and Vaccine Uptake Among Virologically Suppressed People Living with HIV.Vaccines · 2025Article
- Pulmonary Immunocompromise in Human Immunodeficiency Virus Disease.Clinics in chest medicine · 2025Review
- Evolving spectrum of Pneumocystis host specificity, genetic diversity, and evolution.FEMS microbiology reviews · 2025Review
- Chronic Obstructive Pulmonary Disease in People with HIV: an Evidence-Based Review.HIV/AIDS (Auckland, N.Z.) · 2025Review
- Microbiome profiling reveals gut bacterial species associated with rapid lung function decline in people with HIV.Frontiers in immunology · 2025Article
- HIV-associated gut dysbiosis drives oncogenesis through metabolic-immune crosstalk: mechanisms and therapeutic implications.Frontiers in oncology · 2025Review
- DLCO in HIV Patients and Their Association with CD4 and VL.HIV/AIDS (Auckland, N.Z.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 3 countries.
Funding
Abstract
Lung disease encompasses acute, infectious processes and chronic, non-infectious processes such as chronic obstructive pulmonary disease, asthma and lung cancer. People living with HIV are at increased risk of both acute and chronic lung diseases. Although the use of effective antiretroviral therapy has diminished the burden of infectious lung disease, people living with HIV experience growing morbidity and mortality from chronic lung diseases. A key risk factor for HIV-associated lung disease is cigarette smoking, which is more prevalent in people living with HIV than in uninfected people. Other risk factors include older age, history of bacterial pneumonia, Pneumocystis pneumonia, pulmonary tuberculosis and immunosuppression. Mechanistic investigations support roles for aberrant innate and adaptive immunity, local and systemic inflammation, oxidative stress, altered lung and gut microbiota, and environmental exposures such as biomass fuel burning in the development of HIV-associated lung disease. Assessment, prevention and treatment strategies are largely extrapolated from data from HIV-uninfected people. Smoking cessation is essential. Data on the long-term consequences of HIV-associated lung disease are limited. Efforts to continue quantifying the effects of HIV infection on the lung, especially in low-income and middle-income countries, are essential to advance our knowledge and optimize respiratory care in people living with HIV.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.